TW202037378A - 用於遞送阿巴洛帕拉肽(abaloparatide)之經皮傳遞系統及使用方法 - Google Patents
用於遞送阿巴洛帕拉肽(abaloparatide)之經皮傳遞系統及使用方法 Download PDFInfo
- Publication number
- TW202037378A TW202037378A TW109106617A TW109106617A TW202037378A TW 202037378 A TW202037378 A TW 202037378A TW 109106617 A TW109106617 A TW 109106617A TW 109106617 A TW109106617 A TW 109106617A TW 202037378 A TW202037378 A TW 202037378A
- Authority
- TW
- Taiwan
- Prior art keywords
- abalopalatide
- formulation
- patch
- minutes
- zncl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 108010038051 abaloparatide Proteins 0.000 title claims abstract description 10
- BVISQZFBLRSESR-XSCWXTNMSA-N abaloparatide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C1=CN=CN1 BVISQZFBLRSESR-XSCWXTNMSA-N 0.000 title claims abstract description 10
- 229950001959 abaloparatide Drugs 0.000 title claims abstract description 10
- 229940100640 transdermal system Drugs 0.000 title 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims abstract description 40
- 239000011592 zinc chloride Substances 0.000 claims abstract description 22
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 9
- 238000009472 formulation Methods 0.000 claims description 133
- 239000000203 mixture Substances 0.000 claims description 133
- 210000000689 upper leg Anatomy 0.000 claims description 74
- 230000037317 transdermal delivery Effects 0.000 claims description 42
- 238000000576 coating method Methods 0.000 claims description 18
- 235000005074 zinc chloride Nutrition 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 9
- 230000003203 everyday effect Effects 0.000 claims description 8
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 239000013011 aqueous formulation Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 230000037182 bone density Effects 0.000 claims description 3
- 230000002354 daily effect Effects 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 description 39
- 238000007920 subcutaneous administration Methods 0.000 description 36
- 230000009885 systemic effect Effects 0.000 description 27
- 150000003751 zinc Chemical class 0.000 description 21
- 210000001015 abdomen Anatomy 0.000 description 19
- 229920001223 polyethylene glycol Polymers 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 238000013461 design Methods 0.000 description 12
- 230000036470 plasma concentration Effects 0.000 description 12
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 9
- 239000004246 zinc acetate Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000008227 sterile water for injection Substances 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 3
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 235000013904 zinc acetate Nutrition 0.000 description 3
- 239000011667 zinc carbonate Substances 0.000 description 3
- 235000004416 zinc carbonate Nutrition 0.000 description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 description 3
- 239000011670 zinc gluconate Substances 0.000 description 3
- 235000011478 zinc gluconate Nutrition 0.000 description 3
- 229960000306 zinc gluconate Drugs 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 2
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 2
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 2
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 2
- 102000058004 human PTH Human genes 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZOWOHMFPXMYFKJ-WBTWNKCNSA-N (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C1=CN=CN1 ZOWOHMFPXMYFKJ-WBTWNKCNSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 108010054971 parathyroid hormone-related protein (1-34) Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- -1 zinc salt Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812140P | 2019-02-28 | 2019-02-28 | |
| US62/812,140 | 2019-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202037378A true TW202037378A (zh) | 2020-10-16 |
Family
ID=69811437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109106617A TW202037378A (zh) | 2019-02-28 | 2020-02-27 | 用於遞送阿巴洛帕拉肽(abaloparatide)之經皮傳遞系統及使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210379162A1 (enExample) |
| EP (1) | EP3930743A1 (enExample) |
| JP (1) | JP2022521563A (enExample) |
| KR (1) | KR20210134324A (enExample) |
| CN (1) | CN113453704A (enExample) |
| AU (1) | AU2020228339A1 (enExample) |
| BR (1) | BR112021012283A2 (enExample) |
| CA (1) | CA3122239A1 (enExample) |
| CO (1) | CO2021007862A2 (enExample) |
| IL (1) | IL284565A (enExample) |
| MX (1) | MX2021007062A (enExample) |
| SG (1) | SG11202106205YA (enExample) |
| TW (1) | TW202037378A (enExample) |
| WO (1) | WO2020174443A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021149012A1 (en) | 2020-01-24 | 2021-07-29 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
| CN117586377A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效阿巴洛肽化合物 |
| CN119113134B (zh) * | 2024-09-13 | 2025-05-16 | 南京羚诺生物医药技术研究院有限公司 | 一种提升阿巴帕肽半衰期的制备方法及其在治疗骨质疏松症中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20031302A3 (cs) * | 2000-10-13 | 2003-10-15 | Alza Corporation | Prvek zadržující mikrovýčnělkový prvek pro nárazový aplikátor |
| CN101151048A (zh) * | 2004-05-10 | 2008-03-26 | 纳斯泰克制药公司 | 增强甲状旁腺激素粘膜递送的组合物和方法 |
| CA2680690A1 (en) * | 2006-03-15 | 2007-09-20 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia |
| US8563513B2 (en) * | 2009-03-27 | 2013-10-22 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
| JP6214548B2 (ja) * | 2011-11-29 | 2017-10-18 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | 骨再生のための治療補助薬としてのインスリン−疑似剤 |
| WO2017026462A1 (ja) | 2015-08-07 | 2017-02-16 | 京都府公立大学法人 | 褐色脂肪細胞の調製方法 |
| JP7116680B2 (ja) | 2015-10-09 | 2022-08-10 | キンデーバ ドラッグ デリバリー リミティド パートナーシップ | コーティングされたマイクロニードルアレイのための亜鉛組成物 |
| HUE055658T2 (hu) | 2015-10-09 | 2021-12-28 | Radius Health Inc | PTHRP analógokat tartalmazó készítmények, ezeket tartalmazó transzdermális tapaszok és ezek alkalmazása |
| EP3481414B1 (en) * | 2016-04-18 | 2021-11-03 | Radius Health, Inc. | Formulations of abaloparatide, transdermal patches thereof, and uses thereof |
-
2020
- 2020-02-27 BR BR112021012283-4A patent/BR112021012283A2/pt unknown
- 2020-02-27 MX MX2021007062A patent/MX2021007062A/es unknown
- 2020-02-27 EP EP20711326.7A patent/EP3930743A1/en not_active Withdrawn
- 2020-02-27 SG SG11202106205YA patent/SG11202106205YA/en unknown
- 2020-02-27 CA CA3122239A patent/CA3122239A1/en active Pending
- 2020-02-27 AU AU2020228339A patent/AU2020228339A1/en not_active Abandoned
- 2020-02-27 CN CN202080007632.4A patent/CN113453704A/zh active Pending
- 2020-02-27 TW TW109106617A patent/TW202037378A/zh unknown
- 2020-02-27 JP JP2021532151A patent/JP2022521563A/ja active Pending
- 2020-02-27 WO PCT/IB2020/051699 patent/WO2020174443A1/en not_active Ceased
- 2020-02-27 KR KR1020217027861A patent/KR20210134324A/ko active Pending
-
2021
- 2021-06-15 CO CONC2021/0007862A patent/CO2021007862A2/es unknown
- 2021-07-01 IL IL284565A patent/IL284565A/en unknown
- 2021-08-06 US US17/395,516 patent/US20210379162A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN113453704A (zh) | 2021-09-28 |
| IL284565A (en) | 2021-08-31 |
| CA3122239A1 (en) | 2020-09-03 |
| US20210379162A1 (en) | 2021-12-09 |
| CO2021007862A2 (es) | 2021-11-19 |
| MX2021007062A (es) | 2021-09-10 |
| WO2020174443A1 (en) | 2020-09-03 |
| BR112021012283A2 (pt) | 2021-09-08 |
| SG11202106205YA (en) | 2021-07-29 |
| KR20210134324A (ko) | 2021-11-09 |
| EP3930743A1 (en) | 2022-01-05 |
| AU2020228339A1 (en) | 2021-07-01 |
| JP2022521563A (ja) | 2022-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7146011B2 (ja) | ＰＴＨｒＰ類似体の製剤、その経皮パッチ、およびその使用 | |
| JP7139498B2 (ja) | アバロパラチドの製剤、その経皮パッチ、およびその使用 | |
| US20230277444A1 (en) | FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF | |
| US20210379162A1 (en) | Transdermal system for the delivery of abaloparatide and method of use for treating osteoporosis | |
| US10086036B2 (en) | Bleomycin-based compositions and use thereof for treating loose skin and fatty tissue | |
| HK40064524A (en) | Formulations of pthrp analogues, transdermal patches thereof, and uses thereof | |
| HK40072671A (en) | Formulations of abaloparatide, transdermal patches thereof, and uses thereof | |
| HK40008968B (en) | Formulations of abaloparatide, transdermal patches thereof, and uses thereof | |
| HK1260883A1 (en) | Formulations of pthrp analogues. transdermal patches thereof, and uses thereof |